TP53 and lung cancer: 2016), we found that YAP amplification or LATS2 deletion co-occur with oncogenic driver mutations of the TP53 gene (Figure 4), suggesting a possible cooperation between mutp53 and the overexpression or hyperactivation of YAP in lung cancer.